Net Clinical Benefit of Direct Oral Anticoagulants in Patients With Cancer and Venous Thromboembolism: A Systematic Review and Trade-Off Analysis

Background: Venous thromboembolism (VTE) is highly prevalent in cancer patients. Recent guidelines recommend considering direct oral anticoagulants (DOACs) for the treatment of cancer-associated thrombosis (CAT). However, direct head-to-head comparisons among DOACs are lacking, and almost no net cli...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yi-Dan Yan, Zheng Ding, Mang-Mang Pan, Qing Xia, Jiu-Jie Cui, Li-Wei Wang, Chi Zhang, Zhi-Chun Gu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2020-11-01
coleção:	Frontiers in Cardiovascular Medicine
Assuntos:	direct oral anticoagulants (DOACs) cancer venous thromboembolism (VTE) trade-off analysis net clinical benefit (NCB)
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fcvm.2020.586020/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!